Friday 27th

Translating science into better cancer care

Starting today in Barcelona, Spain, the ESMO Congress 2019 aims to focus on novel approaches and breakthroughs that can drive advances along the three-stage course of cancer care, from laboratories to clinical settings and from…

Watch Here

Adding FOLFIRINOX to nab-PG may improve outcomes in pancreatic cancer

“Patients with locally advanced pancreatic cancer must be treated with combination chemotherapy and, until proven otherwise, valid options are FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) and nab-paclitaxel plus gemcitabine (nab-PG). The latter followed by FOLFIRINOX is…

Read More

Universal Health Coverage is not a theoretical problem

Access to healthcare is a human right. However, across the world, people with cancer still struggle to access appropriate care and experience financial hardship due to medical care costs. By facilitating more equitable care and…

Read More